Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE (TM) observational study

Basit Öğe Kaydı
dc.contributor.authorKurtoglu, Selim
dc.contributor.authorAtabek, Mehmet Emre
dc.contributor.authorDizdarer, Ceyhun
dc.contributor.authorPirgon, Ozgur
dc.contributor.authorIsguven, Pinar
dc.contributor.authorEmek, Sevil
dc.date.accessioned2020-03-26T17:38:58Z
dc.date.available2020-03-26T17:38:58Z
dc.date.issued2009
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Insulin detemir is a basal insulin analog designed to produce a superior pharmacokinetic profile to basal formulations of human insulin. It has shown consistently improved tolerability ill comparison to neutral protamine Hagedorn (NPH) insulin in adult cohorts, but there are relatively few publications involving pediatric cohorts. Methods: The efficacy and safety of insulin detemir in children with type I diabetes was assessed using data from the Turkish cohort of PREDICTIVE(TM) (a large, multinational, observational) study. The children investigated were using basal-bolus therapy involving NPH insulin or insulin glargine at baseline but were switched to insulin detemir as part of routine clinical care by their physicians. Results: Twelve weeks of treatment with insulin detemir significantly reduced mean hemoglobin A1c (9.7-8.9%, p < 0.001) and mean fasting glucose [185-162 mg/dL (10.3-9 mmol/L), p < 0.01]. Fasting glucose variability was also lower after treatment with insulin detemir than previously (oil either NPH or glargine, p < 0.05). The frequencies of total, major and nocturnal hypoglycemic events were significantly reduced with insulin detemir relative to baseline, with all estimated mean of 6.89 fewer events/patient/yr overall (p < 0.001) and 2.6 fewer nocturnal events/patient/yr (p < 0.01). Weight and insulin dose remained relatively unchanged. Conclusions: Twelve weeks of treatment with insulin detemir improved glycemic control and reduced hypoglycemia ill children with type I diabetes. This improved tolerability might allow further dose titration and therefore additional improvements in glucose control.en_US
dc.description.sponsorshipNovo NordiskNovo Nordisken_US
dc.description.sponsorshipThe PREDICTIVE study is supported by Novo Nordisk.en_US
dc.identifier.doi10.1111/j.1399-5448.2008.00497.xen_US
dc.identifier.endpage407en_US
dc.identifier.issn1399-543Xen_US
dc.identifier.issn1399-5448en_US
dc.identifier.issue6en_US
dc.identifier.pmid19220776en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage401en_US
dc.identifier.urihttps://dx.doi.org/10.1111/j.1399-5448.2008.00497.x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/23618
dc.identifier.volume10en_US
dc.identifier.wosWOS:000269984100008en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofPEDIATRIC DIABETESen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectdiabetes mellitus type 1en_US
dc.subjecthypoglycemiaen_US
dc.subjectinsulin detemiren_US
dc.subjectpediatricen_US
dc.titleInsulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE (TM) observational studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu